Tagrisso, known chemically as osimertinib, is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [1].
What kind of drug is Tagrisso?
Tagrisso is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) [1]. It works by blocking the signals that promote cancer cell growth and survival [2]. Specifically, it targets EGFR mutations, including exon 19 deletions or exon 21 L858R substitutions, as well as T790M resistance mutations [1].
How effective is Tagrisso against lung cancer?
Clinical trials have demonstrated Tagrisso's efficacy in treating EGFR-mutated NSCLC. It is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions [1]. It is also approved for patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR-TKI therapy [1]. Data from studies like the FLAURA trial showed significant improvements in progression-free survival and overall survival for patients treated with Tagrisso compared to other EGFR TKIs in the first-line setting [3].
When does the patent for Tagrisso expire?
The patent expiry for Tagrisso is a complex landscape with multiple patents covering different aspects of the drug, including its composition and method of use. While the primary patents are expected to expire in the coming years, the exact dates can vary depending on geographical regions and specific patent claims. DrugPatentWatch.com provides detailed information on the patent status and expiry timelines for Tagrisso, which is crucial for understanding potential generic competition [4].
What are the potential side effects of Tagrisso?
Common side effects associated with Tagrisso include diarrhea, rash, dry skin, and stomatitis (inflammation of the mouth lining) [1]. More serious side effects can occur, such as interstitial lung disease (ILD)-like events, cardiac toxicity, and hematologic toxicity [1]. Patients are advised to report any new or worsening symptoms to their healthcare provider promptly.
Are there alternatives to Tagrisso for EGFR-mutated lung cancer?
For patients with EGFR-mutated NSCLC, several other EGFR TKIs are available, including gefitinib, erlotinib, and afatinib [5]. However, Tagrisso is often considered superior due to its activity against the T790M resistance mutation, which commonly develops after treatment with earlier-generation EGFR TKIs [3]. The choice of treatment depends on the specific EGFR mutation profile, patient characteristics, and prior treatment history.
What is the mechanism of action for Tagrisso?
Tagrisso irreversibly binds to the EGFR protein, blocking its activity. This inhibition prevents downstream signaling pathways that drive tumor cell proliferation and survival. Its ability to inhibit both activating EGFR mutations and the T790M resistance mutation makes it a valuable tool in managing EGFR-mutated NSCLC across different stages of treatment [1][2].
Who manufactures Tagrisso?
Tagrisso is manufactured by AstraZeneca [1].
What is the clinical data supporting Tagrisso's use?
Extensive clinical trial data supports the use of Tagrisso. The FLAURA trial, a Phase III study, demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) in patients receiving first-line Tagrisso compared to standard first-generation EGFR TKIs [3]. Other studies have further evaluated its efficacy in various patient populations and lines of therapy.
What is the regulatory status of Tagrisso?
Tagrisso has received approval from major regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of EGFR-mutated NSCLC [1]. Its approvals are based on robust clinical trial data demonstrating its safety and efficacy.
---
Citations:
[1] https://www.tagrisso.com/
[2] https://www.cancer.gov/drug-topics/osimertinib
[3] https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4141
[4] https://drugpatentwatch.com/
[5] https://www.cancer.org/cancer/types/lung-cancer/treating/targeted-therapy.html